Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the safety and the maximum tolerated dose of GRN163L administration in treating patients with refractory or relapsed solid tumor malignancies.


Clinical Trial Description

GRN163L is a telomerase template antagonist with in vitro and in vivo activity in a variety of tumor model systems. Telomerase is an enzyme that is active primarily in tumor cells and is crucial for the indefinite growth of tumor cells. Inhibition of telomerase may result in antineoplastic effects. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00310895
Study type Interventional
Source Geron Corporation
Contact
Status Completed
Phase Phase 1
Start date March 2006
Completion date March 2013

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04668833 - ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter Phase 2
Recruiting NCT05085548 - ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies Phase 1
Completed NCT01924689 - Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies Phase 1
Completed NCT01183364 - A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors Phase 1
Terminated NCT00195156 - Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies Phase 1
Terminated NCT01290380 - A Study to Evaluate the Effects of ASA404 Alone or in Combination With Taxane-based Chemotherapies on the Pharmacokinetics of Drugs in Patients With Advanced Solid Tumor Malignancies Phase 1
Terminated NCT01118819 - Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies Phase 1